A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 20284 participants.
Also called NCT05757869
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 20,284 participants
- Registry
-
NCT05757869 -
2022-501419-15-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Netherlands, New Zealand, Philippines, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Taiwan, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05757869. Randomized; double masking; primary purpose treatment. Start 2023-04-11 (actual); primary completion 2026-12-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- Acronym
- LIBREXIA-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Milvexian
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Apixaban Placebo
- Lead sponsor
- Janssen Research & Development, LLC
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct05757869- Content hash
39aa9854d592da7361e5b4e883b9f76fe96e7156f7b4de57164f192ac362b89d